Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

@inproceedings{Harandi2011SafetyAE,
  title={Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial},
  author={Ali Amini Harandi and Roya Abolfazli and A. Hatemian and K. Ghragozlee and M. Ghaffar-Pour and Maryam Karimi and S. Shahbegi and Hossein Pakdaman and Maryam Akhavan Tabasi and A. L. Tabatabae and Anahid Nourian},
  booktitle={Stroke research and treatment},
  year={2011}
}
Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 3 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months. Results. Sex, age, elapsed time from stroke onset… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Neuroaid in stroke recovery.

European neurology • 2008
View 2 Excerpts

Neuroprotective effects of ginsenosides.

Acta neurobiologiae experimentalis • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…